Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial
复制标题
DOI：
10.1016/s2352-3026(19)30104-8
复制
发表时间：
2019-08-01
影响因子：
24.7
通讯作者：
Brown, Jennifer R.
中科院分区：
文献类型：
--
作者：
Davids, Matthew S.;Brander, Danielle M.;Brown, Jennifer R.
背景：氟达拉滨、环磷酰胺和利妥昔单抗（FCR）可以改善年轻（年龄
Background Fludarabine, cyclophosphamide, and rituximab (FCR) can improve disease-free survival for younger (age